Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

ith the FDA a possible Phase 3 registration trial evaluating first-line docetaxel with and without OGX-011 and the strategy of combining the first-line registration trial with one of the second-line clinical trials for product marketing approval for patients with CRPC. - Secure a development and commercialization partnership for OGX-011 in 2009. - Report data from our ongoing Phase 1 clinical trial evaluating OGX-427 as a monotherapy in patients with solid tumors; these data have been selected for presentation at the American Society of Clinical Oncology 2009 Annual Meeting in the second quarter. - Initiate an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 as a treatment in patients with bladder cancer, in the second quarter.

Financial Results

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of the OncoGenex Pharmaceuticals thereafter.

Research and development expenses for the fourth quarter and year ended December 31, 2008 were $4.2 million and $7.8 million, respectively, compared to $1.1 million and $4.1 million, respectively, in the corresponding periods of 2007. The increases in 2008 were primarily due to manufacturing costs incurred in the fourth quarter of 2008 associated with the development of our product candidate OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus.

General and administrative expenses for the fourth quarter and year ended December 31, 2008 were $1.0 million and $3.3 million, respectively, compared to $0.8 million and $3.5 million, respectively, in the corresponding periods of 2007. The increase for the fourth quarter of
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 2014 ... HCL Industry” is a professional and in-depth research ... provides basic Naltrexone HCL information, including its definition, ... as industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:10/30/2014)... 2014 James Sherley says he has been ... stem cell technology since his days as a principal investigator ... the late 1990’s. Sherley founded the ASCTC as a ... all the intellectual property developed in Sherley’s research over the ... Institute of Technology (MIT), and more recently as a senior ...
Breaking Biology Technology:Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
... Aug. 29 Pharmos Corporation,(Nasdaq: PARS ) ... will,cease operations in Rehovot, Israel, and manage those ... US headquarters in Iselin, New,Jersey., The research ... library,of compounds, including preclinical development of PRS-639,058 for,neuropathic ...
... SAN DIEGO, Aug. 28 Orexigen(R) Therapeutics,Inc. (Nasdaq: ... central nervous system disorders, including obesity, today announced,that the ... BioCentury Newsmakers in the Biotech Industry ... Millennium Broadway Hotel, New York, UBS Global Life ...
... Enerkem Inc., a leading second,generation biofuels technology ... Vice-Presidents to its executive team: Mr. Denis ... Labrie,Vice-President, Government Affairs and Communications., "I ... to our management,team," said Mr. Vincent Chornet, ...
Cached Biology Technology:Pharmos Corporation Announces That it Will Cease Operations in Israel 2Enerkem Expands Executive Management Team 2
(Date:10/31/2014)... Dr. John Schoggins , Assistant Professor of Microbiology at ... Innovator Award from the National Institutes of Health (NIH) ... harbor numerous viruses without becoming sick. , Dr. ... one of 85 awards given under the High Risk/High ... New Innovator Awards were created to support highly creative ...
(Date:10/31/2014)... key steps involved in programmed cell death, offering new ... and neurodegenerative diseases. , The research teams from ... discover the three-dimensional structure of a key cell death ... how it causes cell death. Their studies were published ... Proceedings of the National Academy of Sciences ...
(Date:10/31/2014)... Oct. 30, 2014  HITLAB SM , a ... announce its inaugural HITLAB Innovators Summit SM ... Library. HITLAB will partner with the Clinton Foundation,s ... Health, ProtoHack, Columbia Business School Alumni Club of ... Industrial Engineering and Operations Research, bringing together leaders ...
Breaking Biology News(10 mins):UT Southwestern Microbiologist awarded prestigious NIH research grant 2A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3
... promising new technique to ensure complete tumor removal at ... of Radiology. , Researchers used light waves in a ... examine excised breast tissue and determine if the removed ... This technology has the potential to eliminate the need ...
... different species, evolution whizzes along. As different species ... environment and prosper. It happens in marine sediments, ... in precancerous tumors, too. , In a study ... Ph.D., a researcher at The Wistar Institute, and ...
... a natural mechanism to get inside cells and grow, researchers ... millions of receptors on the cell's surface routinely do after ... Chair in Oncologic Pathology at the Medical College of Georgia. ... 23 by Proceedings of the National Academy of Sciences. , ...
Cached Biology News:Terahertz imaging may reduce breast cancer surgeries 2Researchers create pigs that produce heart-healthy omega-3 fatty acids 2Common bacteria pirate natural mechanism to get inside cells 2
Request Info...
... Concentration Basement Membrane Extract Cultrex HC20+ ... vivo applications where higher protein concentrations ... strength, and elevated levels of tumor ... of lot-to-lot consistency and controlled protein ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
...
Biology Products: